Pen­ny stock biotech miss­es on its sole clin­i­cal tri­al; Cal­adrius teams up with Roche for pan­cre­at­ic can­cer col­lab­o­ra­tion

Vyne Ther­a­peu­tics had put all its clin­i­cal fo­cus on one drug: FMX114 for mild-to-mod­er­ate atopic der­mati­tis. How­ev­er, that tri­al, Vyne’s on­ly on­go­ing clin­i­cal tri­al, has now sunk.

The New Jer­sey biotech put out word Wednes­day that the tri­al failed to meet its pri­ma­ry end­point, list­ed as the change in an atopic der­mati­tis mea­sure (known as AD­SI) over one month. The Phase IIa tri­al en­rolled 21 pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER